Novavax's Newest Covid Vaccine: A Game Changer for the U.S. Market?

The Covid vaccine landscape in the U.S. has experienced a fresh jolt of enthusiasm as Novavax’s newest shot finally receives the green light from regulators.

by Faruk Imamovic
SHARE
Novavax's Newest Covid Vaccine: A Game Changer for the U.S. Market?
© Getty Images News/Carsten Koall

The Covid vaccine landscape in the U.S. has experienced a fresh jolt of enthusiasm as Novavax’s newest shot finally receives the green light from regulators. This breakthrough emerges nearly three weeks after Pfizer and Moderna's new jabs made their public debut, with over 4 million individuals having already been vaccinated in September.

But is it too late for Novavax to make a significant impact on the U.S. market?

Timelines, Delays, and Market Optimism

Despite the somewhat delayed entry of Novavax's vaccine, market experts and Wall Street analysts are far from concerned.

In fact, many opine that Novavax is strategically positioned to rapidly gain ground this fall, potentially outpacing other contenders in the U.S. Covid vaccine scene. Key factors contributing to this optimism include the logistical hurdles that plagued other vaccine rollouts and the FDA's broad accessibility label for the Novavax shot.

Mayank Mamtani, an analyst from B. Riley Securities, voices the general sentiment succinctly, “I’m really not concerned about the timeline or lag relative to the other shots”. Further assuaging concerns, he highlights that the regulatory clearance for Novavax was only marginally behind the company's own third-quarter predictions.

Novavax’s Steady Revival and Unique Positioning

From a broader perspective, this approval signifies a much-needed boon for Novavax. After facing severe financial setbacks and generating skepticism about its viability at the start of the year, this authorization couldn’t have come at a better time.

Banking heavily on the updated Covid vaccine—its sole commercial product—and comprehensive cost-cutting strategies, Novavax aims to solidify its market stance. But there's another ace up Novavax’s sleeve: its vaccine's unique protein-based technology.

Unlike the messenger RNA technology utilized by Pfizer and Moderna, Novavax leverages a tried-and-tested method akin to routine hepatitis B and shingles vaccinations. Silvia Taylor, Novavax’s chief corporate affairs and advocacy officer, underscores the potential of this differentiation: “We have data showing that 25% to 30% of people prefer a protein-based vaccine”.

In the turbulent world of stock markets, Novavax witnessed its shares soar by over 10% immediately after the FDA endorsement. Though the company's stock remains 25% down for the year—after a sharp 90% decline last year—there's palpable excitement about what the future holds for Novavax and the broader public health community.

SHARE